Today's DNA sequencing technologies are becoming more and more impressive. That it is not only important to focus on mutations in the sequence of DNA, however, but also on differences that occur on the level above the genes, the epigenetic modifications of the DNA, has been found out by the researchers of Michael Dyer's group.
The quickly developing childhood cancer retinoblastoma is directly related to the inactivation of the tumor suppressor gene RB1. With RB1 having different roles relevant for understanding this cancer, the process leading to advancing retinoblastoma after its inactivation is not yet understood.
After analysis of the genome and the epigenome of different retinoblastomas, the genome was detected as relatively stable. A newly proposed part of the chain of events leading to the outbreak of this severe cancer is as follows.
Biallelic loss of RB1 leads to the deregulation of epigenetic mechanisms and thereby also of cancer pathways. This is followed by cells acquiring the characteristics of cancer cells. With the experiments conducted by Dyer et al., the proto-oncogene SYK (spleen tyrosine kinase) was found to be upregulated in retinoblastoma and also necessary for the survival of the tumor cells. With SYK inhibited, increasing apoptosis of the cancer cells could be observed. The conclusion seems likely that SYK promises to be a new target for treating retinoblastoma patients and a broader approach in research, including not only genomic data, but also epigenetic analyses, is necessary for better understanding of cancer in the future.
Table of Contents
1. Abstract
2. Introduction
3. Stability of the Retinoblastoma genome
4. Epigenetic Investigations
5. Testing SYK
6. Discussion
7. References
8. Abbreviations and notation
Research Objectives and Topics
This essay explores the molecular mechanisms underlying retinoblastoma progression following the inactivation of the RB1 tumor suppressor gene. It aims to evaluate whether genomic instability or epigenetic modifications are the primary drivers of this childhood cancer and investigates the therapeutic potential of targeting the upregulated proto-oncogene SYK (spleen tyrosine kinase).
- Genomic and epigenomic analysis of retinoblastoma stability
- The role of the RB1 gene in epigenetic regulation
- Identification of SYK as a critical target for tumor cell survival
- Evaluation of small-molecule SYK inhibitors in vitro and in vivo
- Interactions between epigenetic pathways and cancer progression
Excerpt from the Book
3. Stability of the Retinoblastoma genome
Wondering what the cause of the quick progress of the disease after RB1 inactivation could be, Dyer and his group, part of the St Jude Children's Research Hospital (SJCRH) – Washington University Pediatric Cancer Genome Project, took a closer look at the retinoblastomas and their germline DNA of four different patients. They performed whole-genome sequencing (WGS) and found out that the genomes were not significantly instable in comparison to other adult tumors that also have undergone WGS. In fact, the mean mutation rate of the analyzed retinoblastomas was, with only 6.7·10-8, even 15-fold lower than in the common adult malignancies it was compared to.
Loss of heterozygosity (LOH) of RB1 on chromosome 13 and a gain of chromosome 6p were the only found structural variations. This is a surprising result, since genomic instability including chromosomal aberrations as well as many mutations were expected to be crucial for cancer cell development (Murphree, 2012).
42 additional retinoblastomas from SJCRH were used for further studies to support the findings. The BCL-6-co-repressor gene BCOR was the only gene that was noticed to be mutated significantly (13% out of the 42 samples).
Dyer's team used a paired-end sequencing approach and provided supplementary coverage by sequencing the transcriptomes of each primary tumor. Orthotopic xenografts were also generated of two of the samples (SJRB001X and SJRB002X) in order to come to further conclusions in vivo by having similar features of the originals represented in living organisms; immunocompromised mice got primary tumor cells implanted into the vitreous humor of their eyes.
Summary of Chapters
1. Abstract: Provides a concise overview of the research findings, highlighting the relatively stable genome of retinoblastoma and the identification of the proto-oncogene SYK as a viable therapeutic target.
2. Introduction: Introduces the clinical context of retinoblastoma, noting the role of RB1 inactivation and the historical mystery regarding the disease's rapid progression.
3. Stability of the Retinoblastoma genome: Details the genomic sequencing results, which reveal that retinoblastoma possesses a surprisingly stable genome with few mutations compared to other adult malignancies.
4. Epigenetic Investigations: Examines epigenetic modifications in retinoblastoma cells, identifying SYK upregulation as a key event following RB1 loss.
5. Testing SYK: Describes experiments demonstrating that SYK expression is essential for tumor cell survival and that its inhibition induces apoptosis in cancer cells.
6. Discussion: Critically evaluates the findings of the study, noting that while SYK is a promising target, other identified genes like BCOR also warrant further investigation regarding their impact on tumor development.
7. References: A comprehensive list of academic sources and literature used to support the research presented in the essay.
8. Abbreviations and notation: Provides a glossary of technical terms and acronyms used throughout the publication.
Keywords
Retinoblastoma, RB1, SYK, Epigenetics, Cancer Therapy, Genomic Stability, Apoptosis, Tumor Suppressor, BCOR, Kinase Inhibitors, Whole-Genome Sequencing, Molecular Biotechnology, Childhood Cancer, Chromosomal Aberrations, Cell Proliferation.
Frequently Asked Questions
What is the core subject of this paper?
The paper focuses on identifying the molecular drivers of retinoblastoma progression after the loss of the tumor suppressor gene RB1.
What are the central themes discussed?
The central themes include genomic stability vs. epigenetic instability, the role of SYK in tumor survival, and the potential for targeted cancer therapies.
What is the primary goal of the research presented?
The primary goal is to validate SYK as a new therapeutic target for retinoblastoma by proving it is necessary for the survival of cancer cells.
Which scientific methodology does the author refer to?
The research relies on whole-genome sequencing (WGS), chromatin immunoprecipitation (ChIP), transcriptome analysis, and in vivo testing using orthotopic xenografts in mice.
What is the main focus of the middle chapters?
The middle chapters detail the genomic analysis of retinoblastoma tumors and the subsequent experiments testing the efficacy of small-molecule SYK inhibitors like BAY 61-3606.
Which keywords best describe this study?
Key terms include Retinoblastoma, RB1, SYK, Epigenetics, Genomic Stability, and Cancer Therapy.
How does RB1 inactivation contribute to disease progression according to the text?
The author suggests that rather than causing widespread genomic instability, RB1 inactivation leads to a deregulation of epigenetic mechanisms, which in turn alters gene expression pathways such as the upregulation of SYK.
Why are SYK inhibitors considered a potential treatment?
Experiments showed that SYK is highly expressed in retinoblastoma cells and that inhibiting its kinase activity induces apoptosis, while having minimal effect on normal retina tissue.
- Citation du texte
- Sophia Stahl (Auteur), 2012, Epigenetics in Retinoblastoma, Munich, GRIN Verlag, https://www.grin.com/document/205065
